We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CollPlant announced its development program of an antiviral agent for potential treatment of COVID-19 patients. In-vitro early results of CollPlant's formulations showed significant inhibition of avian coronavirus infectivity.